- Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Interventions
- Standard Treatment, AGS-003
- Drug · Biological
- Lead sponsor
- Argos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 88
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 71 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2161–2184
of 13,090
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia A
- Interventions
- Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 6 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
- Conditions
- Parkinson Disease
- Interventions
- Isradipine CR 5mg, Isradipine CR 10mg, Isradipine CR 20mg, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 18
- States / cities
- Sunnyvale, California • New Haven, Connecticut • Jacksonville, Florida + 14 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more
- Conditions
- Mental Illness, Physical Illness
- Interventions
- Facilitated Implementation
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 5,616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 22 more
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Dexamethasone, Aspirin
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more
- Conditions
- Acute Pain
- Interventions
- VX-993, HB/APAP, Placebo (matched to VX-993), Placebo (matched to HB/APAP)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Skin Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Skin Melanoma, Stage IIIC Uveal Melanoma, Stage IV Skin Melanoma, Stage IV Uveal Melanoma
- Interventions
- Epacadostat, MELITAC 12.1 Peptide Vaccine
- Drug · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Durham, North Carolina • Cleveland, Ohio + 1 more
- Conditions
- Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Thyroid Gland Medullary Carcinoma
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 17 more
- Conditions
- Melanoma
- Interventions
- Dabrafenib, Vemurafenib, Trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 704 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more
- Conditions
- Walled Off Pancreatic Necrosis
- Interventions
- AXIOS
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
- Conditions
- Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Nivolumab
- Drug · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- Not listed
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
- Conditions
- Asthma in Children, Asthma Attack
- Interventions
- Wearable stethoscope, Routine Clinical lung Auscultation
- Device · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Ipilimumab, Sargramostim
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 257
- States / cities
- Birmingham, Alabama • Palo Alto, California • Rancho Mirage, California + 197 more
- Conditions
- Lymphoma
- Interventions
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2011
- U.S. locations
- 191
- States / cities
- Anchorage, Alaska • Berkeley, California • Burlingame, California + 127 more
- Conditions
- Cystic Fibrosis
- Interventions
- Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
- Other
- Lead sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
- Conditions
- Depressive Disorder, Major
- Interventions
- BI 1358894, Placebo, Quetiapine
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more
- Conditions
- Cystic Fibrosis
- Interventions
- Dornase alfa, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 36 more
- Conditions
- Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
- Interventions
- Dactinomycin, Doxorubicin Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery, Vincristine Sulfate
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 111 more
- Conditions
- Urinary Tract Infections
- Interventions
- bacterial interference
- Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 15 Years to 64 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Dallas, Texas + 1 more
- Conditions
- Non-24-Hour Sleep-Wake Disorder
- Interventions
- tasimelteon
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Pump therapy
- Device
- Lead sponsor
- Animas Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- La Jolla, California • San Diego, California • Atlanta, Georgia + 3 more
- Conditions
- Cancer
- Interventions
- Aspirin, Placebo
- Drug
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 14,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2024
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 32 more
- Conditions
- Pancreatic Cancer
- Interventions
- Simtuzumab, Gemcitabine, Placebo to match simtuzumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Alhambra, California + 40 more